Novartis India Ltd. (NOVARTIND)
Market Closed
11 Aug, 22:00
MSE MSE Primary XNSE ₹
1,600. 00
-5.2
-0.3239%
₹
28.16B Market Cap
- P/E Ratio
100% Div Yield
27 Volume
- Eps
₹ 1,605.2
Previous Close Want to track NOVARTIND and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
NOVARTIND closed today lower at ₹1,600, a decrease of -0.3239% from yesterday's close, completing a monthly increase of 11.347% or ₹163.05. Over the past 12 months, NOVARTIND stock gained 105.3915%.
NOVARTIND pays dividends to its shareholders, with the most recent payment made on Aug 30, 2025. The next estimated payment will be in In 2 weeks on Aug 30, 2026 for a total of ₹25.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 5.442%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on MSE (INR).
NOVARTIND Chart
People also search for
Novartis India Ltd. (NOVARTIND) FAQ
What is the stock price today?
The current price is ₹1,600.00.
On which exchange is it traded?
Novartis India Ltd. is listed on MSE.
What is its stock symbol?
The ticker symbol is NOVARTIND.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 100%.
What is its market cap?
As of today, the market cap is 28.16B.
Has Novartis India Ltd. ever had a stock split?
No, there has never been a stock split.
Novartis India Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | MSE Exchange | INE234A01025 ISIN |
| India Country | 62 Employees | 23 Jul 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Novartis India Limited is a distinguished healthcare company based in Mumbai, India, functioning under the vast umbrella of Novartis AG. The company has made a formidable mark in the Indian healthcare sector since its inception in 1947, offering a wide range of therapeutic products. Novartis India Limited is recognized for its contributions across various healthcare domains, notably in bone and pain management, transplantation immunology, and neurosciences, catering to a diverse set of medical needs in the region.
Products and Services
- Voveran - This brand spans a gamut of bone and pain management products, offering relief and treatment solutions for various conditions associated with bone health and pain. Voveran stands out for its efficacy in addressing pain-related ailments, making it a trusted name in its category.
- Transplantation Immunology Products:
- Simulect - A key product under this category, Simulect is instrumental in preventing organ rejection in kidney and heart transplant patients.
- Certican - It is designed for the prevention of organ rejection primarily in heart and liver transplant recipients, playing a critical role in transplantation medicine.
- Sandimmun Neoral - This medication is fundamental in preventing organ rejection in transplant patients, ensuring the success and longevity of transplanted organs.
- Myfortic - Myfortic offers a targeted approach in preventing organ rejection in kidney transplant patients, contributing significantly to the field of transplantation immunology.
- Neurosciences Products:
- Tegrital - A leading product in neurosciences, Tegrital is primarily used for the treatment of epilepsy and trigeminal neuralgia, providing relief to patients suffering from these conditions.
- Exelon - This product is aimed at managing Alzheimer's disease and other memory disorders, marking a significant contribution to the treatment of neurodegenerative diseases.
Contact Information
Address: Inspire BKC
Phone: 91 22 50243000
Website: https://www.novartis.in
